Jeff George

Jeff has served as Chief Executive Officer and a Board director at Performance Health since February 2018.  Performance Health is a leader in consumer healthcare and is the largest global manufacturer and distributor of products to the physical therapy, sports medicine, and rehabilitation markets. The company’s products are sold to leading healthcare facilities and practitioners such as physical therapists, athletic trainers, rehab specialists, and chiropractors, as well as direct to consumers across all key brick-and-mortar and online retail channels. Its market-leading brands include Biofreeze, TheraBand, TheraPearl, Cramer, Sammons Preston, and Roylan. The company is owned by Chicago-based private equity firm Madison Dearborn Partners.

Jeff previously served on the Novartis Group Executive Committee from 2008 to 2016, first as Division Head and CEO of Sandoz (2008-2014), Novartis’s $10 billion generic pharmaceuticals and biosimilars subsidiary, and then as Division Head and CEO of Alcon (2014-2016), Novartis’s then $10 billion eye care subsidiary.  Prior to this, he was Head of Emerging Markets at Novartis Pharmaceuticals for the Middle East, Africa, Southeast Asia and CIS, after serving as Vice President and Head of Western & Eastern Europe for Novartis Vaccines.

In both of his divisional CEO roles, Jeff was responsible for leading over 25,000 associates globally across more than 160 countries and had primary line leadership and management responsibility for all functions, regions, and franchises. Sandoz is the second-largest generic pharmaceuticals company globally.  Sandoz sales grew by over $1.7 billion during his tenure to $9.2 billion in 2013 and became the global leader in biosimilars, while attaining #1 positions globally in generic dermatologics, ophthalmics, and injectables.  Alcon was the largest ophthalmology company globally in 2016, operating across the ophthalmic pharmaceuticals, surgical and vision care segments.  Acquired for $52 billion in 2011, Alcon was restructured in 2016, with the $4 billion pharma business moving into Novartis Pharmaceuticals.

Before joining Novartis, Jeff was Senior Director of Strategic Planning and Business Development at Gap Inc., where he led growth, licensing, and European expansion efforts for one of its apparel divisions.  Prior to this he was an Engagement Manager at McKinsey & Company in San Francisco.  Jeff has also worked in emerging markets private equity in South Africa and in Washington, D.C.

Jeff holds an MBA from Harvard Business School and a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), where he studied international economics and emerging markets political economy and was awarded the John W. Watzek fellowship.  He received his B.A. in international relations, magna cum laude and Phi Beta Kappa, from Carleton College. 

Jeff serves on the Board of Directors at Roam Analytics, a Stanford- and venture-backed Silicon Valley machine learning and artificial intelligence healthcare data analytics firm, where he has been a strategic advisor to the CEO since 2015. He served on the Board of Directors for AdvaMed from 2014 to 2016 and is a member of the Young President’s Organization (YPO). He was twice named to Fortune’s “40 under 40” list of up-and-coming leaders. He has lived in seven countries on four continents and is married with two daughters. He enjoys running, coaching soccer, live music, international affairs, meditation, and working with multiple non-profits both nationally and in the Dallas area.